Claims
- 1. A compound of formula I, ##STR20## wherein X is hydrogen, chlorine or bromine,
- R.sub.1 is methyl or ethyl, and
- R.sub.2 is a group NR.sub.3 R.sub.4, wherein
- R.sub.3 is hydrogen or alkyl of 1 to 4 carbon atoms, and
- R.sub.4 is SO.sub.2 R.sub.5,
- wherein R.sub.5 is alkyl of 1 to 4 carbon atoms, mono- to tri-halogenalkyl of 1 to 4 carbon atoms, phenyl, pyridyl, phenyl monosubstituted by halogen or alkoxy of 1 to 4 carbon atoms, or a group NR.sub.6 R.sub.7, wherein each of
- R.sub.6 and R.sub.7 is independently hydrogen or alkyl of 1 to 4 carbon atoms, or
- R.sub.6 and R.sub.7 together are one of the groups (CH.sub.2).sub.n or (CH.sub.2).sub.2 --A--(CH.sub.2).sub.2, wherein
- n is a number from 3 to 7, and
- A is oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms or phenyl,
- or a pharmaceutically acceptable acid addition salt.
- 2. A method of treating Morbus Parkinson in animals which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 3. A method of inhibiting prolactin secretion in animals which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 4. A pharmaceutical composition useful in inhibiting prolactin secretion or treating Morbus Parkinson comprising a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutical carrier or diluent.
- 5. A compound of claim 1, wherein R.sub.2 is ##STR21## wherein R.sub.3.sup.I and R.sub.4.sup.I are alkyl or together --[CH.sub.2 ].sub.n --, wherein n is from 3 to 5.
- 6. A compound of claim 1, wherein R.sub.5 is NR.sub.6 R.sub.7.
- 7. A compound of claim 6, wherein R.sub.6 and R.sub.7 are independently hydrogen or alkyl of 1 to 4 carbon atoms.
- 8. A compound of claim 6, wherein R.sub.6 and R.sub.7 are together a group --[CH.sub.2 ].sub.n --, wherein n is a whole number from 3 to 7.
- 9. A compound of claim 6, wherein R.sub.6 and R.sub.7 are a group --[CH.sub.2 ].sub.2 -A-[CH.sub.2 ].sub.2 --, wherein A is oxygen, sulphur, or nitrogen substituted by alkyl of 1 to 4 carbon atoms or phenyl.
- 10. A compound of claim 9, wherein A is oxygen.
- 11. A compound of claim 9, wherein A is sulphur.
- 12. A compound of claim 9, wherein A is nitrogen substituted by alkyl of 1 to 4 carbon atoms, or phenyl.
- 13. A compound of claim 1, wherein X is hydrogen.
- 14. A compound of claim 1, wherein X is chlorine.
- 15. A compound of claim 1, wherein X is bromine.
- 16. A compound of claim 1, wherein R.sub.1 is methyl.
- 17. A compound of claim 1, wherein R.sub.1 is ethyl.
- 18. The compound of claim 1, which is 6-methyl-8.alpha.-N,N-dimethyl-sulphamylamino ergoline I.
- 19. A compound of claim 1, wherein X is H, R.sub.1 is CH.sub.3 and R.sub.3 is H.
- 20. The compound of claim 1 in which R.sub.1, R.sub.2 and X are CH.sub.3, NR.sub.3 R.sub.4 and H, respectively, where R.sub.3 and R.sub.4 are H and SO.sub.2 NH.sub.2, respectively.
- 21. The compound of claim 1 in which R.sub.1, R.sub.2 and X are CH.sub.3, NR.sub.3 R.sub.4 and H, respectively, where R.sub.3 and R.sub.4 are H and ##STR22## respectively.
- 22. The compound of claim 1 in which R.sub.1, R.sub.2 and X are CH.sub.3, NR.sub.3 R.sub.4 and H, respectively, where R.sub.3 and R.sub.4 are H and ##STR23## respectively.
- 23. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is ##STR24##
- 24. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is NHSO.sub.2 NH-C(CH.sub.3).sub.3.
- 25. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is ##STR25##
- 26. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is ##STR26##
- 27. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is NH SO.sub.2 CF.sub.3.
- 28. The compound of claim 1 in which R.sub.1 is methyl, X is hydrogen and R.sub.2 is NH SO.sub.2 CH.sub.3.
- 29. The compound of claim 1 in which R.sub.1 is methyl, X is bromine and R.sub.2 is ##STR27##
Priority Claims (3)
Number |
Date |
Country |
Kind |
9983/74 |
Jul 1974 |
CHX |
|
11031/74 |
Aug 1974 |
CHX |
|
48/76 |
Jan 1976 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 912,876, filed June 5, 1978 now abandoned, which in turn is a continuation of application Ser. No. 825,598, filed Aug. 19, 1977, now abandoned, which in turn is a continuation of application Ser. No. 725,431, filed Sept. 22, 1976, now abandoned, which in turn is a continuation-in-part of Ser. No. 595,161, filed July 11, 1975, now abandoned.
US Referenced Citations (12)
Foreign Referenced Citations (2)
Number |
Date |
Country |
831488 |
Jan 1976 |
BEX |
1041862 |
Sep 1966 |
GBX |
Non-Patent Literature Citations (1)
Entry |
Clemens et al.; Endocrinology; vol. 94; p. 1171 (1974). |
Continuations (3)
|
Number |
Date |
Country |
Parent |
912876 |
Jun 1978 |
|
Parent |
825598 |
Aug 1977 |
|
Parent |
725431 |
Sep 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
595161 |
Jul 1975 |
|